Clinical Trial Search

Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline — -6.00; -4.96…

Primary: Change in the Total Clinical Score From Baseline to Day 22 — -2.8; -1.9; -1.5; -1.8 units on a scale

Primary: Change in Total Clinical Score From Baseline to Day 22 — -3.6; -3.7; -4.9; -1.3 units on a scale

Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — 2.38; -4.76; 2.48; -4.17 Percent Change

Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001

Primary: Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From…

Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…

Primary: Percent Change From Baseline in Psoriasis Assessment of Severity Index (PASI) at Week 12 — -28.043; -37.361 percentage change — p=0.8495

Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants

Primary: Change in Histology

Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at…

Primary: Treatment Emergent Adverse Events (TEAEs) During the Treatment Phase — 25; 13; 3; 1 participants

Primary: Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline — 13.7…

Primary: The Absolute Change in Total Clinical Score (TCS) at End of Treatment Compared to Baseline for Daivobet® Ointment — -5.15 Scores on a scale

Primary: Percentage (%) of Participants Who Achieved Greater Than or Equal (>=) to 75% Improvement From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12 — 5; 0…

Primary: Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24 — 552; 496 Participants — p=0.1499

Primary: 75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 — 1; 4 Participants

Primary: Number of Participants With Clinical Improvement of Target Lesions — 18 Participants

Primary: Percentage of Participants Who Achieved Success in Physician's Global Assessment (PGA) of Disease Severity at Day 84 — 17.4; 13.6 percentage of participants

Primary: Adrenal Suppression Potential — 16; 18; 5; 3 participants

Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — -53.97; -41.01; -24.26; -17.24 percent change

Primary: At Least a One Grade Improvement for the Target Psoriasis Lesion on the Elbow or Knee (Psoriasis Grading Scale) — 15; 14 participants

Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants

Primary: Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1) — -1.60; -4.96; -3.04; -3.96 score on a scale — p=<0.001

Primary: Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week…

Primary: The Number of Subjects Who Achieve a 50% Reduction in the Palmoplantar Psoriasis Severity Index at 12 Weeks. — 8; 12 participants

Primary: Change From Baseline in Psoriatic Skin Thickness/Echo-Poor Band (EPB) for PF-06263276 4% Solution in Comparison to Corresponding Vehicle at Day 12 — 358.9; 353.1; 17.7…

Primary: Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 — 5.8; 18.0; 44.2…

Primary: Modified NAPSI Score (Nail Psoriasis Severity Index) — 6.3; 6.0 units on a scale

Primary: Change in Physicians Global Assessment (PGA) From Baseline to Week 2 and Week 4 — 20; 0; 0; 0 Participants